# UK Montelukast API Market > UK Montelukast API Market Research Repor By Application (Asthma, Allergic Rhinitis, Bronchospasm, Urticaria, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.49% - **2024:** $ 55.55 Million - **2025:** $ 58.6 Million - **2035:** $ 100 Million - **Key Players:** Merck & Co (US), Teva Pharmaceutical Industries (IL), Mylan N.V. (US), Sandoz (CH), Aurobindo Pharma (IN), Cipla (IN), Hikma Pharmaceuticals (GB), Zydus Cadila (IN) **Report ID:** MRFR/HC/51331-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/uk-montelukast-api-market-53092 --- ## Market Summary ## **UK Montelukast API Market Overview** As per MRFR analysis, the UK Montelukast API Market Size was estimated at 33.75 (USD Million) in 2023. The UK Montelukast API Market Industry is expected to grow from 37.88 (USD Million) in 2024 to 117.32 (USD Million) by 2035. The UK Montelukast API Market CAGR (growth rate) is expected to be around 10.825% during the forecast period (2025 - 2035). ## **Key UK Montelukast API Market Trends Highlighted** The UK Montelukast API market is experiencing a rising trend of research and development activities designed to enhance the therapeutic application of Montelukast. The demand for effective treatments has increased due to the rise in respiratory diseases, particularly asthma and allergic rhinitis, which has resulted in a greater need for active pharmaceutical ingredients (API) of higher quality. The UK government has prioritized the reduction of the burden of respiratory diseases, which is consistent with the market drivers promoting the development of innovative therapies and improved formulations. Additionally, the recent emphasis on sustainability in pharmaceutical manufacturing is generating opportunities in the UK Montelukast API market. Companies are investigating methods to improve the environmental impact of their production processes, which could potentially appeal to environmentally conscious consumers and regulatory bodies. This trend is indicative of a more generalized change in the UK pharmaceutical sector, as businesses are becoming more inclined to implement green chemistry practices. Additionally, the most recent advancements in biopharmaceuticals are resulting in a more targeted and efficient formulation of Montelukast. Montelukast is also being utilized in new ways as a result of the market's transition to personalized medication. Montelukast's function in treatment regimens based on individual patient needs is a significant opportunity to re-evaluate as healthcare in the UK transitions to more tailored approaches. Furthermore, the expansion of telemedicine in the United Kingdom is enabling enhanced patient access to prescription medications, which in turn expands the availability of Montelukast APIs. The ongoing partnership between the National Health Service (NHS) and pharmaceutical corporations is facilitating the advancement of healthcare delivery and patient awareness of available treatments. This convergence of trends suggests that the UK market for Montelukast APIs is dynamic and constantly changing. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ## **UK Montelukast API Market Drivers** ### **Increasing Prevalence of Respiratory Diseases** The UK is witnessing a rise in respiratory diseases, with asthma affecting approximately 8 million people. According to the UK Asthma Organization, hospital admissions for asthma-related issues have increased by 36% over the past decade. This rise in respiratory conditions significantly drives demand in the UK Montelukast API Market Industry, as Montelukast is a widely used medication for both asthma and allergic rhinitis. Major pharmaceutical companies such as GlaxoSmithKline and AstraZeneca are actively involved in Research and Development (R&D) for improved asthma management solutions, hence aligning with market growth strategies to cater to the increasing patient needs. ### **Government Initiatives to Improve Public Health** The UK government has implemented various initiatives aimed at improving respiratory health, including the National Health Service's commitment to reducing asthma-related hospital admissions by 20% in five years. This policy creates a favorable environment for the UK [Montelukast API Market](../../../reports/montelukast-api-market-7886) Industry, stimulating innovation and production of Montelukast APIs. The collaboration of prominent organizations like NHS England and Public Health England ensures continuous funding and support for pharmaceutical development, thereby enhancing the availability of Montelukast and contributing to market expansion. ### **Growing Awareness and Patient Education** In the UK, there is a concerted effort towards educating the population about asthma management and the use of medications such as Montelukast. Initiatives led by organizations like the Asthma UK charity emphasize the importance of proper care and treatment. Research indicates that better patient awareness can improve adherence to medication regimens by 25%, thereby increasing the demand for Montelukast in the UK Montelukast API Market Industry. This increase in demand encourages pharmaceutical companies to invest more in the development of Montelukast APIs, further driving market growth. ## **UK Montelukast API Market Segment Insights** ### **Montelukast API Market Application Insights** The UK Montelukast API Market exhibits significant growth within its Application segment, driven primarily by the increasing prevalence of respiratory and allergic conditions within the region. This demand is particularly pronounced in patients who have asthma, a predominant condition that accounts for a considerable proportion of Montelukast's usage. Asthma remains a key driver for the market, as it affects a significant number of individuals across the UK, necessitating effective treatment options to manage symptoms and improve quality of life. Allergic rhinitis is another critical area of focus, impacting millions and leading to substantial healthcare costs. The rising awareness about the adverse effects of environmental allergens has amplified the need for efficacious treatment, such as Montelukast, further solidifying its importance in the market landscape. Bronchospasm, a condition often related to asthma, is gaining recognition for its distinct treatment needs, prompting ongoing research to understand its dynamics and therapeutic options. Additionally, urticaria is drawing attention due to its potential chronic nature in some patients, thus increasing treatment cycles and patient engagement with healthcare providers. The 'Others' category encompasses various minor yet significant applications, which together could reflect niche but valuable areas of treatment requiring advanced APIs like Montelukast. Market trends suggest that innovative delivery methods and formulations will be increasingly essential to address the diverse needs of patients experiencing these conditions. With growing investment in Research and Development within the pharmaceutical industry, the UK Montelukast API Market is poised to experience transformative changes aimed at improving patient compliance and achieving better clinical outcomes. Overall, the Application segment of the UK Montelukast API Market illustrates a complex landscape bolstered by medical advancement, the necessity for effective therapeutic options, and a heightened focus on patient-centric healthcare solutions. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ## **UK Montelukast API Market Key Players and Competitive Insights** The competitive landscape of the UK Montelukast active pharmaceutical ingredient (API) market is characterized by a dynamic array of factors influencing player strategies, market entry, and growth trajectories. Montelukast is primarily used for treating asthma and allergic rhinitis, leading to a steady demand for this API within the UK’s healthcare framework. The market is marked by significant competition among various pharmaceutical and API manufacturers, each striving to enhance their manufacturing capabilities, optimize production operations, and meet regulatory requirements. As the UK continues to emphasize generic products, this presents opportunities for companies that can successfully leverage cost efficiencies and product innovation. Market participants are increasingly focusing on sustainability practices and supply chain robustness to align with the emerging healthcare paradigms in the region. Sandoz International GmbH plays a vital role in the UK Montelukast API market, showcasing a strong commitment to quality and affordability in its product offerings. With a robust manufacturing and distribution network, Sandoz has established a commendable market presence, ensuring reliable supply and adherence to stringent regulatory standards. The company's reputation for delivering high-quality generics, particularly in the respiratory segment, enhances its competitive position within the market. Sandoz is recognized for its strategic investments in research and development, which significantly contribute to its strengths in product diversification and innovation. Such investments not only enhance product efficacy but also enable the company to remain responsive to evolving market demands and patient needs throughout the UK. Granules India Ltd has carved a significant niche for itself in the UK Montelukast API market by leveraging its extensive experience and capabilities in the pharmaceutical sector. The company offers a wide range of high-quality APIs, including Montelukast, which are essential for various therapeutic applications. Granules India Ltd gains a competitive edge through its focus on vertical integration, which allows for cost-effective production and sustainable practices. Its strategic partnerships and potential mergers fortify the company’s market presence, which enhances its R&D infrastructure and expands its reach within the UK market. Granules India Ltd is dedicated to maintaining high standards in manufacturing and compliance, which bolsters its reputation. Additionally, the company’s commitment to innovation in API production aligns with the demands of the UK regulatory landscape, providing a strong foundation for future growth and expansion in the sector. ### **Key Companies in the UK Montelukast API Market Include** ## **UK Montelukast API Market Industry Developments** In recent months, the UK Montelukast Active Pharmaceutical Ingredient (API) Market has seen significant developments. Granules India Ltd and Dr. Reddy's Laboratories announced an increased focus on production capabilities in the UK in response to rising demand for respiratory therapies, driven by the prevalence of asthma and allergies. Teva Pharmaceutical Industries Ltd has also reported a boost in its market presence, launching new formulations of Montelukast to cater to diverse patient needs. Additionally, in July 2023, Merck Sharp and Dohme Corp announced a strategic collaboration with Aurobindo Pharma to enhance their shared capabilities in the Montelukast segment, aimed at improving efficiency and market response. The UK government has implemented regulatory adjustments to streamline the approval processes for generic alternatives, positively impacting the participation of companies such as Cipla Ltd and Hetero Labs Limited. Over the last two years, the market has experienced a valuation growth attributed largely to increased awareness of respiratory diseases and the high demand for affordable treatment options. These factors combined illustrate a rapidly evolving landscape for the Montelukast API Market in the UK, with key players adjusting strategies to capture emerging opportunities. ## **UK Montelukast API Market Segmentation Insights** ### **Montelukast API Market Application Outlook** ## Market Drivers ### Cost-Effectiveness of Montelukast The montelukast api market benefits from the cost-effectiveness of montelukast as a treatment option for asthma and allergic rhinitis. Compared to other therapeutic alternatives, montelukast is often more affordable, making it accessible to a broader patient population. The NHS has been focusing on cost containment strategies, which include promoting the use of generic medications. As montelukast is available in generic forms, it is likely to be a preferred choice for healthcare providers and patients alike. This cost advantage may lead to increased prescriptions and, consequently, a positive impact on the montelukast api market. Furthermore, the economic burden of untreated asthma and allergies on the healthcare system underscores the importance of effective and affordable treatment options, further solidifying montelukast's position in the market. ### Growing Awareness of Preventive Healthcare There is a notable shift towards preventive healthcare in the UK, which is positively influencing the montelukast api market. Patients and healthcare providers are increasingly recognizing the importance of early intervention in managing chronic conditions such as asthma. Montelukast, being a preventive treatment, aligns well with this trend. Educational campaigns by health organizations and the NHS are raising awareness about the benefits of using montelukast for long-term asthma control. This growing emphasis on preventive measures is likely to enhance the market for montelukast, as more patients seek proactive solutions to manage their respiratory health. The integration of montelukast into asthma management plans may become more prevalent, further driving its demand in the montelukast api market. ### Regulatory Support for Generic Medications the montelukast api market is influenced by regulatory support for generic medications in the UK.. The Medicines and Healthcare products Regulatory Agency (MHRA) has streamlined the approval process for generics, facilitating quicker market entry. This regulatory environment encourages pharmaceutical companies to produce montelukast in its generic form, which is often more affordable for patients. As a result, the availability of generic montelukast is likely to increase, leading to greater market penetration. The emphasis on generic medications aligns with the NHS's objectives to reduce healthcare costs while maintaining treatment efficacy. Consequently, the montelukast api market may see a surge in demand as healthcare providers and patients opt for cost-effective treatment options. ### Increasing Prevalence of Asthma and Allergies The montelukast api market is experiencing growth due to the rising prevalence of asthma and allergic conditions in the UK. Recent studies indicate that approximately 8.5% of adults and 12% of children in the UK are diagnosed with asthma, leading to a heightened demand for effective treatments. Montelukast, as a leukotriene receptor antagonist, plays a crucial role in managing these conditions. The increasing awareness of asthma management and the importance of adherence to treatment regimens further drive the montelukast api market. Additionally, the National Health Service (NHS) has been promoting the use of effective asthma medications, which may contribute to the market's expansion. As the population ages and environmental factors contribute to respiratory issues, the demand for montelukast is likely to continue its upward trajectory. ### Technological Advancements in Drug Formulation Technological advancements in drug formulation are playing a pivotal role in shaping the montelukast api market. Innovations in drug delivery systems, such as improved oral formulations and inhalation devices, enhance the efficacy and patient compliance of montelukast. These advancements may lead to better therapeutic outcomes, thereby increasing the attractiveness of montelukast as a treatment option. Furthermore, research into novel formulations that improve bioavailability and reduce side effects could expand the market potential for montelukast. As pharmaceutical companies invest in research and development to leverage these technologies, the montelukast api market is likely to benefit from enhanced product offerings and increased patient satisfaction. ## Future Outlook The [Montelukast API Market](https://www.marketresearchfuture.com/reports/montelukast-api-market-7886) is projected to grow at a 5.49% CAGR from 2025 to 2035, driven by increasing asthma prevalence and rising healthcare expenditures. **New opportunities:** - Expansion into telehealth platforms for prescription management. - Development of combination therapies to enhance efficacy. - Investment in sustainable manufacturing processes to reduce costs. By 2035, the montelukast API market is expected to achieve robust growth and increased market share. ## Segment Insights ### By Application: Asthma (Largest) vs. Allergic Rhinitis (Fastest-Growing) The market share distribution within the application segment of the UK montelukast api market shows that asthma remains the dominant application, accounting for a significant portion of the overall demand. Following asthma, allergic rhinitis is witnessing a notable increase in share, driven by rising allergy incidences and awareness regarding treatment options. Other applications such as bronchospasm and urticaria have smaller yet vital segments, contributing to the overall diversity in therapeutic use of montelukast. Growth trends indicate that the application of montelukast in treating allergic rhinitis is emerging as a key area of expansion, characterized by an increasing diagnosis rate and innovative marketing strategies. The tendency towards preventive healthcare among patients and healthcare providers is further catalyzing the demand for montelukast in managing allergic conditions, positioning allergic rhinitis as a fast-growing segment that complements the established dominance of asthma in therapeutic applications. Asthma: Dominant vs. Allergic Rhinitis: Emerging Asthma represents the dominant application in the UK montelukast api market due to its high prevalence and established treatment protocols that favor this therapeutic route. Prescribing patterns heavily favor montelukast for asthma management, supported by extensive clinical guidelines advocating its use. In contrast, allergic rhinitis is rapidly emerging as a significant segment, fueled by increased awareness and improved diagnostic practices. This segment is characterized by a growing patient population seeking effective allergy management solutions, signaling a shift in treatment preferences that could reshape market dynamics in the coming years. ## Competitive Benchmarking the montelukast api market is characterized by a competitive landscape that is evolving and complex.. Key growth drivers include the increasing prevalence of asthma and allergic rhinitis, alongside a rising demand for cost-effective therapeutic options. Major players such as Merck & Co (US), Teva Pharmaceutical Industries (IL), and Hikma Pharmaceuticals (GB) are strategically positioned to leverage their extensive research capabilities and established market presence. Merck & Co (US) focuses on innovation through continuous research and development, while Teva Pharmaceutical Industries (IL) emphasizes its global reach and diverse product portfolio. Hikma Pharmaceuticals (GB) is enhancing its operational focus on expanding its generic offerings, which collectively shapes a competitive environment that is increasingly reliant on innovation and strategic partnerships.Key business tactics within the montelukast API market include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several key players exerting influence over pricing and distribution channels. This fragmentation allows for a variety of competitive strategies, as companies seek to differentiate themselves through quality, reliability, and service. In October Merck & Co (US) announced a strategic partnership with a leading biotechnology firm to develop a novel formulation of montelukast aimed at improving patient compliance. This collaboration is significant as it not only enhances Merck's product offerings but also positions the company to capture a larger share of the market by addressing patient needs more effectively. The focus on patient-centric solutions is likely to resonate well in a market that increasingly values therapeutic efficacy and user experience. In September Teva Pharmaceutical Industries (IL) launched a new manufacturing facility in the UK dedicated to the production of montelukast API. This move is indicative of Teva's commitment to localizing its supply chain, which may enhance its responsiveness to market demands and reduce lead times. By investing in local production capabilities, Teva is likely to strengthen its competitive position and improve its ability to meet regulatory requirements more efficiently. In August Hikma Pharmaceuticals (GB) expanded its distribution network in Europe, focusing on increasing access to its montelukast products. This strategic expansion is crucial as it allows Hikma to tap into new markets and enhance its visibility among healthcare providers. The emphasis on expanding distribution channels suggests a proactive approach to capturing market share in a competitive landscape where accessibility is paramount. As of November current competitive trends in the montelukast API market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in manufacturing processes. Strategic alliances are shaping the landscape, enabling companies to pool resources and expertise to drive innovation. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident, suggesting that future competitive differentiation will hinge on the ability to innovate and adapt to changing market dynamics. ## Recent News & Developments In recent months, the UK Montelukast Active Pharmaceutical Ingredient (API) Market has seen significant developments. Granules India Ltd and Dr. Reddy's Laboratories announced an increased focus on production capabilities in the UK in response to rising demand for respiratory therapies, driven by the prevalence of asthma and allergies. Teva Pharmaceutical Industries Ltd has also reported a boost in its market presence, launching new formulations of Montelukast to cater to diverse patient needs. Additionally, in July 2023, Merck Sharp and Dohme Corp announced a strategic collaboration with Aurobindo Pharma to enhance their shared capabilities in the Montelukast segment, aimed at improving efficiency and market response. The UK government has implemented regulatory adjustments to streamline the approval processes for generic alternatives, positively impacting the participation of companies such as Cipla Ltd and Hetero Labs Limited. Over the last two years, the market has experienced a valuation growth attributed largely to increased awareness of respiratory diseases and the high demand for affordable treatment options. These factors combined illustrate a rapidly evolving landscape for the Montelukast API Market in the UK, with key players adjusting strategies to capture emerging opportunities. ## Report Scope | MARKET SIZE 2024 | 55.55(USD Million) | | --- | --- | | MARKET SIZE 2025 | 58.6(USD Million) | | MARKET SIZE 2035 | 100.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.49% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Merck & Co (US), Teva Pharmaceutical Industries (IL), Mylan N.V. (US), Sandoz (CH), Aurobindo Pharma (IN), Cipla (IN), Hikma Pharmaceuticals (GB), Zydus Cadila (IN) | | Segments Covered | Application | | Key Market Opportunities | Growing demand for montelukast API driven by increasing respiratory disorders and regulatory support for generic formulations. | | Key Market Dynamics | Regulatory changes and competitive pressures shape the montelukast API market dynamics in the UK. | | Countries Covered | UK | ## Frequently Asked Questions **Q: What was the market valuation of the UK montelukast API market in 2024?** A: The market valuation was $55.55 Million in 2024. **Q: What is the projected market valuation for the UK montelukast API market by 2035?** A: The projected valuation for 2035 is $100.0 Million. **Q: What is the expected CAGR for the UK montelukast API market during the forecast period 2025 - 2035?** A: The expected CAGR is 5.49% during the forecast period 2025 - 2035. **Q: Which companies are the key players in the UK montelukast API market?** A: Key players include Merck & Co, Teva Pharmaceutical Industries, Mylan N.V., Sandoz, Aurobindo Pharma, Cipla, Hikma Pharmaceuticals, and Zydus Cadila. **Q: What application segment had the highest valuation in the UK montelukast API market in 2024?** A: The Asthma application segment had the highest valuation at $22.22 Million in 2024. **Q: What is the projected growth for the Allergic Rhinitis segment in the UK montelukast API market?** A: The Allergic Rhinitis segment is projected to grow from $11.11 Million in 2024 to $20.0 Million by 2035. **Q: How does the Bronchospasm segment perform in the UK montelukast API market?** A: The Bronchospasm segment had a valuation of $8.33 Million in 2024 and is expected to reach $15.0 Million by 2035. **Q: What is the valuation range for the Urticaria segment in the UK montelukast API market?** A: The Urticaria segment had a valuation range of $5.55 Million to $10.0 Million in 2024. **Q: What does the 'Others' segment represent in the UK montelukast API market?** A: The 'Others' segment had a valuation range of $8.34 Million to $15.0 Million in 2024. **Q: How do the key players influence the UK montelukast API market?** A: Key players like Merck & Co and Teva Pharmaceutical Industries likely drive innovation and competition within the UK montelukast API market. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/uk-montelukast-api-market-53092*